We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$855M
AUM Growth
-$19.9M
Cap. Flow
-$111M
Cap. Flow %
-12.98%
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$11.2M
2
ABMD
Abiomed Inc
ABMD
+$9.03M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.67M
4
EXAS
Exact Sciences
EXAS
+$8.51M
5
MGNX icon
MacroGenics
MGNX
+$7.35M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.1M
2
INCY icon
Incyte
INCY
+$13.5M
3
CELG
Celgene Corp
CELG
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$12.4M
5
EXEL icon
Exelixis
EXEL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.64%
2 Technology 0.15%
3 Energy 0.14%
4 Financials 0.1%
5 Communication Services 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$30.5M 3.57%
123,400
-2,996
-2% -$764K
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.9B
$26.8M 3.13%
187,171
+21,353
+13% +$2.79M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$121B
$26.6M 3.11%
144,400
+11,975
+9% +$2.21M
ABMD
4
DELISTED
Abiomed Inc
ABMD
$26.4M 3.09%
92,493
+27,183
+42% +$9.03M
CI icon
5
Cigna
CI
$73.7B
$25.7M 3%
159,691
– –
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$24.8M 2.91%
939,973
-6,087
-0.6% -$144K
NKTR icon
7
Nektar Therapeutics
NKTR
$2.39B
$24.7M 2.89%
48,963
+14,630
+43% +$8.67M
LIVN icon
8
LivaNova
LIVN
$4.4B
$23.4M 2.74%
240,600
+120,000
+100% +$11.2M
NVCR icon
9
NovoCure
NVCR
$1.73B
$21.9M 2.56%
454,647
-90,353
-17% -$4.35M
ELV icon
10
Elevance Health
ELV
$81.5B
$21.1M 2.47%
73,645
-5,000
-6% -$1.45M
ABT icon
11
Abbott
ABT
$183B
$20.7M 2.43%
259,552
-5,000
-2% -$372K
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.6B
$20.6M 2.41%
231,549
+55,000
+31% +$5.1M
HUM icon
13
Humana
HUM
$43.7B
$20.5M 2.4%
77,000
-5,400
-7% -$1.56M
ESPR
14
DELISTED
Esperion Therapeutics
ESPR
$19.3M 2.25%
479,767
+125,806
+36% +$5.64M
CVS icon
15
CVS Health
CVS
$133B
$19.1M 2.23%
353,868
-55,000
-13% -$3.39M
BDX icon
16
Becton Dickinson
BDX
$45.6B
$18.7M 2.19%
76,875
-41,000
-35% -$9.69M
GKOS icon
17
Glaukos
GKOS
$9.83B
$18.5M 2.16%
235,579
-5,000
-2% -$334K
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
$18.4M 2.16%
136,466
-93,963
-41% -$11.7M
MGNX icon
19
MacroGenics
MGNX
$235M
$17.4M 2.03%
967,186
+425,000
+78% +$7.35M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.8B
$15.6M 1.82%
177,091
-24,000
-12% -$2.01M
MDT icon
21
Medtronic
MDT
$109B
$15.4M 1.8%
168,842
-131,561
-44% -$11.8M
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
$14.8M 1.73%
607,070
-90,300
-13% -$1.88M
BSX icon
23
Boston Scientific
BSX
$69.5B
$14.1M 1.65%
367,908
-10,000
-3% -$382K
AGN
24
DELISTED
Allergan plc
AGN
$13M 1.52%
88,600
-10,000
-10% -$1.45M
LLY icon
25
Eli Lilly
LLY
$1.02T
$12.8M 1.5%
98,695
-25,000
-20% -$3.04M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rhenman & Partners Asset Management held 101 positions worth $855M, down 2.3% from $875M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $111M in Q1 2019, closing 8 positions and reducing 38 holdings. Its most notable exit was Biogen, an estimated $18.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Technology and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Exact Sciences worth $8.66M.

  • Rhenman & Partners Asset Management's largest Q1 2019 buy was Exact Sciences: 100,000 shares worth $8.66M.
  • Rhenman & Partners Asset Management added most to LivaNova in Q1 2019, an estimated $11.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2019 reduction was Incyte, cutting an estimated $13.5M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q1 2019, selling an estimated $18.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $855M portfolio in Q1 2019.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 8 in Q1 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 2.3% quarter-over-quarter to $855M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.